ACM
BTAI icon

ACT Capital Management’s BioXcel Therapeutics BTAI Stock Holding History

ACT Capital Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,250
Closed -$418K – 85
2022
Q1 		$418K Hold
1,250
– – 0.44% 37
2021
Q4 		$407K Sell
1,250
-1,875
-60% -$805K 0.29% 49
2021
Q3 		$1.52M Buy
3,125
+500
+19% +$220K 0.79% 30
2021
Q2 		$1.22M Buy
+2,625
New +$1.43M 0.63% 35

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

ACT Capital Management's BTAI Position: Q2 2022 in Review

ACT Capital Management sold out of BioXcel Therapeutics (BTAI) in Q2 2022, closing a stake of 1,250 shares — an estimated $418K sold.

ACT Capital Management first reported a position in BTAI in Q2 2021 and held it in 4 quarters. The position peaked at $1.52M in Q3 2021. 94 funds tracked by Wall St. Rank hold BTAI as of Q2 2022.

  • ACT Capital Management reported no remaining BioXcel Therapeutics position as of Q2 2022 after selling out during the quarter.
  • ACT Capital Management sold 1,250 BioXcel Therapeutics shares in Q2 2022, an estimated $418K.
  • ACT Capital Management first reported a position in BioXcel Therapeutics in Q2 2021 and held it in 4 quarters.
  • ACT Capital Management's BioXcel Therapeutics position peaked at $1.52M in Q3 2021.
  • 94 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2022.

Based on ACT Capital Management's 13F filing for Q2 2022, filed 12 Aug 2022.